Fear of going blind may be more likely to motivate teenagers to stop smoking than the fear of heart or lung disease.
Fear of going blind may be more likely to motivate teenagers to stop smoking than the fear of heart or lung disease, according to a report published online ahead of print by the British Journal of Ophthalmology.
Simon Kelly from the Bolton Eye Unit, UK, led a collaboration of UK and New Zealand based researchers who developed a cross-sectional survey using a structured interview of teenagers attending four organised social events. They investigated the awareness and fear of blindness, lung cancer, heart disease, stroke and a distracter condition (deafness). The aim was to establish the likelihood of whether smokers would quit on developing early signs of the various conditions.
Of the 260 16- to 18-year olds that were interviewed, 15%, 27% and 81% believed smoking caused stroke, heart disease and lung cancer, respectively. Just 5% thought that smoking caused blindness. Subjects were asked to rank their fear of each of the conditions, a score of five for the most feared and one for the least feared. Researchers found that subjects were significantly more fearful of blindness than of lung cancer, heart disease and deafness. Additionally, more teenagers said they would give up smoking if they developed early signs of blindness.
The researchers concluded that emphasizing the risk of blindness is more likely to encourage teenagers to stop smoking than by stressing the risks of lung and hearts disease.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.